DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Pembrolizumab
Drug: Ipilimumab

First Posted Date: 2016-04-19

Last Posted Date: 2024-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 70

Registration Number: NCT02743819

Locations: 🇺🇸
Oncology Specialists S.C., Park Ridge, Illinois, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
Mount Sinai Medical Center of Florida, Miami Beach, Florida, United States

and more 7 locations

Vitamin D and Disease Activity in Ulcerative Colitis

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2016-03-24

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 248

Registration Number: NCT02717897

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Phase 1

Terminated

Conditions: Pleural Mesothelioma

Interventions: Drug: Pembrolizumab
Drug: Cisplatin and Pemetrexed

First Posted Date: 2016-03-14

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 7

Registration Number: NCT02707666

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Phase 2

Terminated

Conditions: FGFR1 Gene Amplification
FGFR2 Gene Amplification
FGFR2 Gene Mutation
Head and Neck Squamous Cell Carcinoma
FGFR Gene Amplification
Recurrent Nasopharynx Carcinoma
FGFR3 Gene Mutation
Human Papillomavirus Infection
Recurrent Head and Neck Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma

Interventions: Drug: BGJ398

First Posted Date: 2016-03-11

Last Posted Date: 2019-04-16

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT02706691

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy

Not Applicable

Completed

Conditions: Congestive Heart Failure

Interventions: Device: CRT Pacemaker

First Posted Date: 2016-03-07

Last Posted Date: 2021-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 41

Registration Number: NCT02700425

Locations: 🇺🇸
Edward Hospital, Naperville, Illinois, United States
🇺🇸
Baptist Health Louisville, Louisville, Kentucky, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 5 locations

Mitigating Hunger and Food Insecurity Among Socioeconomically Disadvantaged Caregivers of Hospitalized Children

Not Applicable

Withdrawn

Conditions: Health Behavior

Interventions: Other: Feed1st

First Posted Date: 2016-03-07

Last Posted Date: 2017-05-12

Lead Sponsor: University of Chicago

Registration Number: NCT02700802

Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing

Phase 2

Withdrawn

Conditions: Anastomotic Leak
Rectal Cancer

Interventions: Drug: Cipro, metronidazole, neomycin combo
Procedure: Serial Endoscopic Surveillance
Drug: Saline

First Posted Date: 2016-02-15

Last Posted Date: 2023-04-26

Lead Sponsor: University of Chicago

Registration Number: NCT02682485

Public Health Targeting of PrEP at HIV Positives' Bridging Networks

Not Applicable

Completed

Conditions: HIV

Interventions: Behavioral: PrEP Intervention

First Posted Date: 2016-02-08

Last Posted Date: 2020-01-09

Lead Sponsor: University of Chicago

Target Recruit Count: 308

Registration Number: NCT02676167

Locations: 🇬🇷
Angelos Hatzakis, Athens, Greece

Remediating Academic Skill Deficits Among Disadvantaged Youth

Not Applicable

Conditions: Educational Achievement

Interventions: Other: SAGA Innovations

First Posted Date: 2016-02-04

Last Posted Date: 2017-07-11

Lead Sponsor: University of Chicago

Target Recruit Count: 1848

Registration Number: NCT02673645

A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

Phase 1

Withdrawn

Conditions: Malignant Pleural Mesothelioma (MPM)

Interventions: Biological: Multipeptide vaccine S-588210

First Posted Date: 2016-01-22

Last Posted Date: 2018-05-14

Lead Sponsor: University of Chicago

Registration Number: NCT02661659

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy